Replies to post #164642 on Biotech Values

[DewDiligence]

VRTX thinks they have enough data to ultimately get the 200mg dose off of hold (assume part of that is the actual data in EU patients at 200mg dose plus other pre-clinical data).

I would take the other side of that bet. The plasma concentration of VX-135 in the dosing range in question is approximately linear, and a 0.5x safety margin (200mg relative to 400mg) is not a lot.